TY - JOUR
T1 - Incidence of Clinically Relevant Thyroid Cancers Remains Stable for Almost a Century
T2 - A Population-Based Study
AU - Genere, Natalia
AU - El Kawkgi, Omar M.
AU - Giblon, Rachel E.
AU - Vaccarella, Salvatore
AU - Morris, John C.
AU - Hay, Ian D.
AU - Brito, Juan P.
N1 - Funding Information:
Grant Support: This study used the resources of the Rochester Epidemiology Project (REP) medical records-linkage system, which is supported by the National Institute on Aging (NIA; AG 058738), by the Mayo Clinic Research Committee, and by fees paid annually by REP users. The content of this article is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health (NIH) or the Mayo Clinic.
Funding Information:
We thank the Karl-Erivan Haub Family Career Development Award in Cancer Research at Mayo Clinic in Rochester for funding this research. Grant Support: This study used the resources of the Rochester Epidemiology Project (REP) medical records-linkage system, which is supported by the National Institute on Aging (NIA; AG 058738), by the Mayo Clinic Research Committee, and by fees paid annually by REP users. The content of this article is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health (NIH) or the Mayo Clinic.
Funding Information:
We thank the Karl-Erivan Haub Family Career Development Award in Cancer Research at Mayo Clinic in Rochester for funding this research.
Publisher Copyright:
© 2021 Mayo Foundation for Medical Education and Research
PY - 2021/11
Y1 - 2021/11
N2 - Objective: To examine the trends in incidence of clinically relevant thyroid cancers within the overall rising incidence of thyroid cancers. Patients and Methods: This is a population-based cohort study conducted using the Rochester Epidemiology Project database to identify all new cases of thyroid cancer in Olmsted County, Minnesota, between January 1, 1935, and December 31, 2018. We extracted information about demographics and tumor pathologic type, size, and invasiveness. Clinically relevant cancers included aggressive histology or presence of metastatic disease, size larger than 4 cm, and gross extrathyroidal tumor invasion. Results: Between 1935 and 2018, 596 thyroid cancer cases were diagnosed (mean age, 46.4 years; 72% female; 87% papillary cancers; and median tumor size, 1.5 cm). The sex- and age-adjusted incidence of thyroid cancer increased from 1.3 per 100,000 person-years (p-y) from 1935–1949 to 12.0 per 100,000 p-y in 2010–2018, corresponding to an absolute change per decade of 1.4 (95% CI, 0.7 to 2.2). There was a nonsignificant period absolute change for patients with tumor greater than 4 cm (0.03; 95% CI, -0.2 to 0.3), with evidence of tumor invasion (0.1; 95% CI, -0.1 to 0.4), and with aggressive histology or presence of metastatic disease (0.2; 95% CI, -0.1 to 0.6). Thyroid cancer mortality was unchanged over the observation period. Conclusion: Incidence rates of clinically relevant thyroid cancers, as defined by histology, size, and invasiveness, have not changed significantly in 80 years. The rising thyroid cancer incidence is driven by indolent thyroid cancers.
AB - Objective: To examine the trends in incidence of clinically relevant thyroid cancers within the overall rising incidence of thyroid cancers. Patients and Methods: This is a population-based cohort study conducted using the Rochester Epidemiology Project database to identify all new cases of thyroid cancer in Olmsted County, Minnesota, between January 1, 1935, and December 31, 2018. We extracted information about demographics and tumor pathologic type, size, and invasiveness. Clinically relevant cancers included aggressive histology or presence of metastatic disease, size larger than 4 cm, and gross extrathyroidal tumor invasion. Results: Between 1935 and 2018, 596 thyroid cancer cases were diagnosed (mean age, 46.4 years; 72% female; 87% papillary cancers; and median tumor size, 1.5 cm). The sex- and age-adjusted incidence of thyroid cancer increased from 1.3 per 100,000 person-years (p-y) from 1935–1949 to 12.0 per 100,000 p-y in 2010–2018, corresponding to an absolute change per decade of 1.4 (95% CI, 0.7 to 2.2). There was a nonsignificant period absolute change for patients with tumor greater than 4 cm (0.03; 95% CI, -0.2 to 0.3), with evidence of tumor invasion (0.1; 95% CI, -0.1 to 0.4), and with aggressive histology or presence of metastatic disease (0.2; 95% CI, -0.1 to 0.6). Thyroid cancer mortality was unchanged over the observation period. Conclusion: Incidence rates of clinically relevant thyroid cancers, as defined by histology, size, and invasiveness, have not changed significantly in 80 years. The rising thyroid cancer incidence is driven by indolent thyroid cancers.
KW - epidemiology
KW - incidence
KW - mortality
KW - thyroid cancer
UR - http://www.scopus.com/inward/record.url?scp=85118133477&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2021.04.028
DO - 10.1016/j.mayocp.2021.04.028
M3 - Article
C2 - 34736609
AN - SCOPUS:85118133477
SN - 0025-6196
VL - 96
SP - 2823
EP - 2830
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 11
ER -